Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
NCT03074318 is a phase 1/2 interventional trial sponsored by Fred Hutchinson Cancer Center. As of 21 Nov 2026, it was terminated. It studies Avelumab and Trabectedin in Metastatic Leiomyosarcoma, Metastatic Liposarcoma and 2 more conditions. The registry lists an enrollment of 35 participants at 1 site in 1 country. The registry lists a start date of 28 Sept 2017 and a primary completion date of 15 Nov 2020. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT03074318 |
| Status | Terminated |
| Phase | Phase 1/2 |
| Study type | Interventional trial |
| Lead sponsor | Fred Hutchinson Cancer Center |
| Enrollment | 35 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Metastatic Leiomyosarcoma, Metastatic Liposarcoma, Unresectable Leiomyosarcoma and Unresectable Liposarcoma |
| Drugs | Avelumab and Trabectedin |
| Start | 28 Sept 2017 |
| Primary completion | 15 Nov 2020 |
| Study completion | 15 Nov 2020 |
| Last update posted | 29 Apr 2022 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Fred Hutch/university of Washington Cancer Consortium
Seattle
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT03074318
Each answer restates registry values shown on this page.
What is NCT03074318?
NCT03074318 is a phase 1/2 interventional trial sponsored by Fred Hutchinson Cancer Center. It studies Avelumab and Trabectedin in Metastatic Leiomyosarcoma, Metastatic Liposarcoma and 2 more conditions.
Who leads NCT03074318?
The registry names Seth Pollack (principal investigator, Northwestern University) as the overall official.
Where does NCT03074318 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT03074318 study?
The registered drug and biological interventions are Avelumab and Trabectedin.
When did NCT03074318 end?
The registry lists a primary completion date of 15 Nov 2020 and a study completion date of 15 Nov 2020. The sponsor last updated the record on 29 Apr 2022.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.